Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $5,484,039.04 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 12,128 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the completion of the transaction, the executive vice president owned 21,264 shares in the company, valued at $9,615,155.52. This represents a 36.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Thursday, October 2nd, Kevin Joseph Fitzgerald sold 2,441 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $452.05, for a total transaction of $1,103,454.05.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $460.76 on Thursday. The firm has a market cap of $60.87 billion, a price-to-earnings ratio of -186.54 and a beta of 0.30. The company’s fifty day moving average is $458.35 and its 200-day moving average is $388.21. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ALNY. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $243,000. Mutual of America Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 673.9% in the first quarter. Mutual of America Capital Management LLC now owns 13,644 shares of the biopharmaceutical company’s stock worth $3,684,000 after acquiring an additional 11,881 shares during the last quarter. Lindbrook Capital LLC increased its position in Alnylam Pharmaceuticals by 9.2% during the first quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 50 shares during the period. Allianz Asset Management GmbH raised its stake in Alnylam Pharmaceuticals by 100.7% during the 1st quarter. Allianz Asset Management GmbH now owns 218,503 shares of the biopharmaceutical company’s stock valued at $59,000,000 after purchasing an additional 109,632 shares during the last quarter. Finally, SYM FINANCIAL Corp raised its stake in Alnylam Pharmaceuticals by 5.3% during the 1st quarter. SYM FINANCIAL Corp now owns 1,014 shares of the biopharmaceutical company’s stock valued at $274,000 after purchasing an additional 51 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ALNY has been the topic of several analyst reports. Needham & Company LLC increased their target price on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. The Goldman Sachs Group raised their price objective on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a research note on Tuesday, September 16th. JPMorgan Chase & Co. decreased their target price on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research report on Monday, October 13th. Finally, Citigroup increased their price target on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Twenty-three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $482.17.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.